<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620980</url>
  </required_header>
  <id_info>
    <org_study_id>RF-2019-12370224</org_study_id>
    <nct_id>NCT04620980</nct_id>
  </id_info>
  <brief_title>Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease</brief_title>
  <official_title>Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease: a Novel Diagnostic Test to Predict Parkinson's Disease Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project intends to assess the polygenic burden of rare disruptive mutations in&#xD;
      Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to extend the genetic analysis to a cohort of 300 PD cases and 300&#xD;
      healthy subjects (wife / husband of the patients) that will be recruited at Scientific&#xD;
      Institute for Research, Hospitalization and Healthcare (IRCCS) Neuromed.&#xD;
&#xD;
      After signed informed consent patients will be assessed for disease progression (Hoehn and&#xD;
      Yahr stadium, Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III&#xD;
      (MDS-UPDRS), Montreal Cognitive Assessment (MoCA) test, no motor symptoms, therapy and&#xD;
      levodopa induced Dyskinesia (LID) occurrence). Each patient and control will be subjected to&#xD;
      peripheral blood sampling for the isolation of DNA, RNA, plasma and serum. The investigators&#xD;
      will use a disease-specific gene panel including about 100 genes related to Parkinson's&#xD;
      Disease, autophagy and levodopa induced Dyskinesia (LID).&#xD;
&#xD;
      Bioinformatics analysis will allow to catalog in a database the identified variants/mutations&#xD;
      according to their frequency and characteristics.&#xD;
&#xD;
      The investigators will specifically assess if the inheritance of multiple rare deleterious&#xD;
      variants in Parkinson's Disease genes is predictive of disease risk.&#xD;
&#xD;
      The presence of one or more variants will be tested for association with phenotypic&#xD;
      manifestation of Parkinson's Disease (motor, non-motor, and cognitive signs, as well as age&#xD;
      at onset, LID and neuroimaging changes) to assess the variant burden effect on progression,&#xD;
      and prognosis of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>clinical evaluation of PD patients and controls</measure>
    <time_frame>three years</time_frame>
    <description>disease progression (Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>identification of variants/mutations</measure>
    <time_frame>two years</time_frame>
    <description>assessing if the inheritance of multiple rare deleterious variants in PD genes is predictive of PD risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>association with phenotypic manifestation of PD</measure>
    <time_frame>three years</time_frame>
    <description>The presence of one or more variants will be tested for association with phenotypic manifestation of PD (motor, non-motor, and cognitive signs, as well as age at onset, LID and neuroimaging changes) to assess the variant burden effect on progression, and prognosis of the disease.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.&#xD;
Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.&#xD;
DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.&#xD;
DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>targeted resequencing</intervention_name>
    <description>The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for purification of DNA, RNA, plasma and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study includes 300 PD patients and 300 age/gender-matched controls. All PD patients&#xD;
        will be diagnosed at the IRCCS Neuromed and followed-up (at least for 3 years) for disease&#xD;
        progression.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of at least two out the following cardinal signs: resting tremor, cogwheel&#xD;
             rigidity, bradykinesia, asymmetrical onset of symptoms and symptomatic response to&#xD;
             L-dopa (levodopa).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous thalamotomy on the implanted sides;&#xD;
&#xD;
          -  Significant brain atrophy or structural damage seen on CT or MRI;&#xD;
&#xD;
          -  Marked cognitive dysfunction;&#xD;
&#xD;
          -  Active psychiatric symptoms;&#xD;
&#xD;
          -  Concurrent neurological disorders;&#xD;
&#xD;
          -  Other uncontrolled medical disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Esposito, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of CNR Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Esposito, PhD</last_name>
    <phone>+39 0865915249</phone>
    <email>teresa.esposito@igb.cnr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Esposito, PhD</last_name>
      <phone>0865915249</phone>
      <email>teresa.esposito@igb.cnr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Teresa Esposito</investigator_full_name>
    <investigator_title>Head of CNR Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>genetics data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

